Patient characteristics
| Characteristic . | HD15 analysis set AS1, no. (%) (n = 817) . | PET analysis set AS2, no. (%) (n = 311) . | NPV analysis set AS3, no. (%) (n = 275) . | |||
|---|---|---|---|---|---|---|
| Age group, y | ||||||
| 18-20 | 59 | (7.2) | 28 | (9) | 27 | (9.8) |
| 20-30 | 267 | (32.7) | 120 | (38.6) | 99 | (36.0) |
| 30-40 | 229 | (28.0) | 102 | (32.8) | 92 | (33.5) |
| 40-50 | 154 | (18.9) | 47 | (15.1) | 44 | (16.0) |
| 50-60 | 102 | (12.5) | 14 | (4.5) | 13 | (4.7) |
| Sex | ||||||
| Female | 318 | (38.9) | 129 | (41.5) | 112 | (40.7) |
| Male | 499 | (61.1) | 182 | (58.5) | 163 | (59.3) |
| Stage | ||||||
| IIB | 136 | (16.7) | 94 | (30.2) | 80 | (29.1) |
| IIIA | 192 | (23.5) | 54 | (17.4) | 48 | (17.5) |
| IIIB | 210 | (25.7) | 63 | (20.3) | 57 | (20.7) |
| IVA | 77 | (9.4) | 33 | (10.6) | 32 | (11.6) |
| IVB | 202 | (24.7) | 67 | (21.5) | 58 | (21.1) |
| Reference histology | ||||||
| Missing | 113 | (13.8) | 52 | (16.7) | 42 | (15.3) |
| LP | 26 | (3.2) | 2 | (0.6) | 2 | (0.7) |
| cHL | 65 | (8.0) | 28 | (9.0) | 25 | (9.1) |
| NS cHL | 418 | (51.2) | 173 | (55.6) | 154 | (56.0) |
| LR cHL | 16 | (2.0) | 3 | (1.0) | 2 | (0.7) |
| MC cHL | 174 | (21.3) | 50 | (16.1) | 47 | (17.1) |
| LD cHL | 5 | (0.6) | 3 | (1.0) | 3 | (1.1) |
| Characteristic . | HD15 analysis set AS1, no. (%) (n = 817) . | PET analysis set AS2, no. (%) (n = 311) . | NPV analysis set AS3, no. (%) (n = 275) . | |||
|---|---|---|---|---|---|---|
| Age group, y | ||||||
| 18-20 | 59 | (7.2) | 28 | (9) | 27 | (9.8) |
| 20-30 | 267 | (32.7) | 120 | (38.6) | 99 | (36.0) |
| 30-40 | 229 | (28.0) | 102 | (32.8) | 92 | (33.5) |
| 40-50 | 154 | (18.9) | 47 | (15.1) | 44 | (16.0) |
| 50-60 | 102 | (12.5) | 14 | (4.5) | 13 | (4.7) |
| Sex | ||||||
| Female | 318 | (38.9) | 129 | (41.5) | 112 | (40.7) |
| Male | 499 | (61.1) | 182 | (58.5) | 163 | (59.3) |
| Stage | ||||||
| IIB | 136 | (16.7) | 94 | (30.2) | 80 | (29.1) |
| IIIA | 192 | (23.5) | 54 | (17.4) | 48 | (17.5) |
| IIIB | 210 | (25.7) | 63 | (20.3) | 57 | (20.7) |
| IVA | 77 | (9.4) | 33 | (10.6) | 32 | (11.6) |
| IVB | 202 | (24.7) | 67 | (21.5) | 58 | (21.1) |
| Reference histology | ||||||
| Missing | 113 | (13.8) | 52 | (16.7) | 42 | (15.3) |
| LP | 26 | (3.2) | 2 | (0.6) | 2 | (0.7) |
| cHL | 65 | (8.0) | 28 | (9.0) | 25 | (9.1) |
| NS cHL | 418 | (51.2) | 173 | (55.6) | 154 | (56.0) |
| LR cHL | 16 | (2.0) | 3 | (1.0) | 2 | (0.7) |
| MC cHL | 174 | (21.3) | 50 | (16.1) | 47 | (17.1) |
| LD cHL | 5 | (0.6) | 3 | (1.0) | 3 | (1.1) |
LP indicates lymphocyte predominant HL; cHL, classic Hodgkin's lymphoma; NS, nodular sclerosis; LR, lymphocyte rich classic HL; MC, mixed cellularity; and LD, lymphocyte depletion.